Notices to creditors (MVL)
VIMELA THERAPEUTICS LIMITED
The notice informs creditors of VIMELA THERAPEUTICS LIMITED that, in a members’ voluntary liquidation, they must submit proof of debt by 6 August 2026 to the appointed liquidator, James Hopkirk of Kreston Reeves LLP.
Notice details
- Company
- VIMELA THERAPEUTICS LIMITED
- Company number
- 13611487
- Nature of business
- Research and experimental development on biotechnology
- Type of liquidation
- Members voluntary liquidation
- Registered office
- The Cambridge Partnership The Dorothy Hodgkin Building, Babraham Research Campus, Cambridge, CB22 3FH
- Principal trading address
- The Cambridge Partnership The Dorothy Hodgkin Building, Babraham Research Campus, Cambridge, Cambridgeshire, CB22 3FH
- Liquidator
- James Hopkirk (IP No. 21150) of Kreston Reeves LLP, 2nd Floor Maritime Place, Quayside, Chatham Maritime, Kent, ME4 4QZ
- Date of appointment
- 30 June 2026
- Contact
- Mansi Thawani, 01634 899800, [email protected]
Planning a solvent wind-down or restructure?
A members' voluntary liquidation is a solvent, orderly closure — often part of retirement, a group restructure, or moving on to the next venture. K2 has advised UK company directors since 1990 on restructuring and what comes next. If that's on your horizon, talk to us.
Related guidance
Free, practical guides from K2 on what this kind of notice means for directors.
More liquidation notices
Source: The London Gazette and Companies House. Contains public sector information licensed under the Open Government Licence v3.0. © Crown copyright. This page is provided by K2 Partners for information only and is not legal or financial advice.